Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Proteome Sciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Proteome Sciences.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Life Sciences kazanç büyümesi	25.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

May 10

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Proteome Sciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

AIM:PRM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	4	-4	-2	-2	N/A
3/31/2024	5	-3	-1	-1	N/A
12/31/2023	5	-2	-1	0	N/A
9/30/2023	6	-1	1	1	N/A
6/30/2023	8	1	2	2	N/A
3/31/2023	8	1	2	2	N/A
12/31/2022	8	1	2	2	N/A
9/30/2022	7	1	2	2	N/A
6/30/2022	6	1	2	2	N/A
3/31/2022	6	0	1	1	N/A
12/31/2021	5	0	1	1	N/A
9/30/2021	5	0	1	1	N/A
6/30/2021	5	0	1	1	N/A
3/31/2021	5	0	1	1	N/A
12/31/2020	5	0	2	2	N/A
9/30/2020	5	0	1	1	N/A
6/30/2020	5	0	1	1	N/A
3/31/2020	5	0	0	0	N/A
12/31/2019	5	0	0	0	N/A
9/30/2019	4	0	0	0	N/A
6/30/2019	3	0	0	0	N/A
3/31/2019	3	-1	0	0	N/A
12/31/2018	3	-1	-1	-1	N/A
9/30/2018	3	-2	0	0	N/A
6/30/2018	3	-2	0	0	N/A
3/31/2018	3	-2	N/A	-1	N/A
12/31/2017	3	-2	N/A	-2	N/A
9/30/2017	3	-2	N/A	-2	N/A
6/30/2017	3	-2	N/A	-3	N/A
3/31/2017	3	-2	N/A	-2	N/A
12/31/2016	3	-2	N/A	-2	N/A
9/30/2016	2	-3	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	2	-3	N/A	-2	N/A
12/31/2015	2	-3	N/A	-2	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	-3	N/A	-3	N/A
3/31/2015	2	-3	N/A	-3	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	2	-3	N/A	-3	N/A
6/30/2014	2	-3	N/A	-3	N/A
3/31/2014	2	-3	N/A	-3	N/A
12/31/2013	2	-3	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if PRM's forecast earnings growth is above the savings rate (1.9%).

Kazançlar ve Piyasa: Insufficient data to determine if PRM's earnings are forecast to grow faster than the UK market

Yüksek Büyüme Kazançları: Insufficient data to determine if PRM's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if PRM's revenue is forecast to grow faster than the UK market.

Yüksek Büyüme Geliri: Insufficient data to determine if PRM's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if PRM's Return on Equity is forecast to be high in 3 years time

Proteome Sciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Recent updates

New major risk - Market cap size

New major risk - Revenue and earnings growth

Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

New major risk - Share price stability

Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)

Proteome Sciences plc, Annual General Meeting, May 16, 2024

New minor risk - Financial data availability

New major risk - Share price stability

Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching

Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling Reagents

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)

Now 43% undervalued

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Less than half of directors are independent

Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?

Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial Officer

First half 2022 earnings released

Proteome Sciences plc Completes Milestone Towards Launch of single Cell Proteomics Services

Less than half of directors are independent

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)

Proteome Sciences plc, Annual General Meeting, May 16, 2022

Now 25% undervalued after recent price drop

Proteome Sciences plc to Report Fiscal Year 2021 Results on Mar 31, 2022

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)

Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?

Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E

Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin